June 22, 2018 08:59 AM EDT
Financing
R&D

Boehringer backs €20B R&D game plan with a $272M blue­print for new fa­cil­i­ty — 100 new hires

John Carroll

Editor & Founder

Boehringer In­gel­heim is back­ing their bi­o­log­ics fo­cus in R&D with a $272 mil­lion in­vest­ment in a new fa­cil­i­ty that will add an­oth­er 100 staffers to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Pfiz­er, GSK add risk of Guil­lain-Bar­ré to RSV vac­cine la­bels at FDA's re­quest

A service from the Financial Times